The At-Risk Launch: When the Math Says Go Even If the Court Says No
In branded pharma, timing isnt just strategyits math. And nowhere does that math get sharper, riskier, and more consequential than the decision to launch at risk, even when a courts a…

Evergreening isnt a conspiracyits a pattern. Heres how to spot the cracks in a 20‑patent thicket.
The pharmaceutical industry is built on timelines: filing, approvals, exclusivity, andeventuallycompetition. But in the real world, competition is often…

Most patent enforcement stories start with a headline: a big win, a major settlement, a court victory.
But the most valuable outcomes often happen quietlybefore a full infringement case ever reaches a final judgment.
The article on DrugPatentWatchSue…

The 180-day exclusivity trap: why first-to-file winners still lose money
In pharma, we tell a comforting story: file first, win exclusivity, collect the payoff.
But the realityespecially for ANDA and 505(b)(2) follow-on strategiesis messier. The 180-da…

Drug patent litigation is one of those domains where winning is easy to say and hard to execute. Its also where companies can accidentally train themselves to accept a costly default: assume settlements are inevitable, price the risk internally as just…

Drug patents are supposed to be fortresses. But the first crack usually isnt at the strongest wallits at the weakest one.
In the classic story, patents fail because the science moves faster than the claims. In practice, they often fail because enforcem…

Most new drug patents dont create new drugs. They create new barriers.
The pharmaceutical patent system is often described as a balance: enough protection to reward innovation, enough freedom to let patients access medicines sooner. But in practice, a …

Pediatric exclusivity was supposed to be a shield. In practice, its too often a fuseburning value, delaying competition, and reshaping incentives in ways policymakers didnt fully anticipate.
When people hear pediatric exclusivity, they tend to think …

Bausch Healths recent patent battle with Sun Pharma isnt just another courtroom updateits a playbook for how the next phase of branded-drug value will be defended.
And the market is already reacting.
Heres the core point: when generics and biosimilars …

Agitation: Patent battles are often framed as technical footnotesclaim charts, priority dates, likelihood of infringement. But for pharma companies, these disputes decide something much more immediate: who gets to sell a medicine, when, and at what pri…